Viking Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company, is advancing a dual GLP-1/GIP agonist, VK2735, for treating obesity for both subcutaneous and oral administration
Take a deeper dive into each phase and discover the process we use to take your health to the next level
Additional testing may help provide a diagnosis
This chart breaks down the common themes we see in compounded semaglutide reviews
A doctor reviews your health history and checks for contraindications before deciding whether it is suitable for you
Covered by Medicare Most patients pay little to nothing* Visits with your assigned licensed provider Monthly check-ins and ongoing care management Cellular-connected smart scale and remote monitoring Continuous glucose monitors (Dexcom G7, FreeStyle Libre) for those who qualify Metabolic lab testing to guide your care Billed to Medicare, not to you